Additional studies based on larger sample sizes and patients with different ethnicities are needed to further evaluate the association between genetic polymorphisms in EGFR and the prognosis of glioma and astrocytoma patients in larger samples. This evidence concerns the gene EGFR and central nervous system cancer.